

# Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Jeffrey I. Campbell<sup>1</sup> · Christina Yau<sup>2</sup> · Polina Krass<sup>3</sup> · Dan Moore<sup>2</sup> · Lisa A. Carey<sup>4</sup> · Alfred Au<sup>2</sup> · David Chhieng<sup>5</sup> · Dilip Giri<sup>6</sup> · Chad Livasy<sup>4</sup> · Carolyn Mies<sup>7</sup> · Joseph Rabban<sup>2</sup> · Venetia R. Sarode<sup>8</sup> · Baljit Singh<sup>9</sup> · Laura Esserman<sup>2</sup> · Yunn-Yi Chen<sup>2</sup>

Received: 12 May 2017 / Accepted: 16 May 2017 / Published online: 2 June 2017  
© Springer Science+Business Media New York 2017

## Abstract

**Purpose** Several pathologic staging systems characterize residual tumor in patients undergoing neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two other systems of post-neoadjuvant pathologic tumor staging—residual cancer burden (RCB) and the American Joint Committee on Cancer post-neoadjuvant

therapy staging system (yAJCC)—have been developed to characterize residual tumors when patients do not achieve pCR. The optimal system and the ways in which these systems complement each other have not been fully determined. **Methods** Using data from the I-SPY 1 TRIAL, we compared pCR, RCB, and yAJCC as predictors of early recurrence-free survival (RFS) to identify ways to improve post-neoadjuvant pathologic evaluation.

**Results** Among 162 patients assessed, pCR identified patients at lowest risk of recurrence, while RCB and yAJCC identified patients at highest risk. Hormone-receptor (HR) and HER2 subtypes further improved risk prediction. Recursive partitioning indicated that triple-negative or HER2+ patients with yAJCC III or RCB 3 have the highest recurrence risk, with an RFS of 27%. Our analysis also highlighted discrepancies between RCB and yAJCC stratification: 31% of patients had discrepant RCB and yAJCC scores. We identified differential treatment of lymph node involvement and tumor cellularity as drivers of these discrepancies.

**Conclusions** These data indicate that there is benefit to reporting both RCB and yAJCC for patients in order to identify those at highest risk of relapse.

**Electronic supplementary material** The online version of this article (doi:10.1007/s10549-017-4303-8) contains supplementary material, which is available to authorized users.

Affiliation at the time the authors (David Chhieng and Chad Livasy) did the work.

✉ Yunn-Yi Chen  
Yunn-Yi.Chen@ucsf.edu

- <sup>1</sup> Boston Medical Center and Boston Children's Hospital, Boston, MA, USA
- <sup>2</sup> University of California, San Francisco, CA, USA
- <sup>3</sup> Children's Hospital of Philadelphia, Philadelphia, PA, USA
- <sup>4</sup> University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- <sup>5</sup> Yale School of Medicine, New Haven, CT, USA
- <sup>6</sup> Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- <sup>7</sup> University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
- <sup>8</sup> University of Texas Southwestern Medical Center, Dallas, TX, USA
- <sup>9</sup> New York University School of Medicine, New York, NY, USA

**Keywords** Breast neoplasm · Neoadjuvant therapy · Local neoplasm recurrence · Residual neoplasm · Cancer staging · Lymph nodes · Disease-free survival · Residual cancer burden · Pathologic complete response

## Introduction

Several pathologic staging systems have been developed to risk-stratify patients following completion of neoadjuvant chemotherapy for breast cancer (Table 1). The most

**Table 1** Summary of post-neoadjuvant pathologic staging systems

Staging System	Abbreviation	Categories	Components
American Joint Committee on Cancer	yAJCC	0, I (a–b), II (a–b), III (a–c), IV	T—tumor size, invasion of local structures N—nodal metastases M—distant metastases
Residual cancer burden	RCB	0, 1, 2, 3	Tumor size Tumor cellularity Nodal metastases
Pathologic complete response	pCR	Absent, present	Any residual tumor

commonly used and extensively evaluated system—pathologic complete response (pCR) [1, 3, 4, 10, 14]—is defined as the absence of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy [6]. Patients with this response to chemotherapy have a demonstrably lower risk of tumor recurrence than patients with residual carcinoma [18]. When accompanied by results from definitive trials, the Food and Drug Administration (FDA) recognizes pCR as an endpoint for granting accelerated approval in neoadjuvant chemotherapy trials in order to shorten the time to evaluate new chemotherapeutic agents [5, 13]. However, by definition, pCR does not distinguish among patients with residual tumor. Two other staging systems—residual cancer burden (RCB) and the American Joint Committee on Cancer post-neoadjuvant staging (yAJCC)—do stratify patients with residual cancer.

RCB reports a score based on the fraction of the tumor bed area that contains invasive carcinoma excluding in situ disease (“cellularity”), the dimensions of the tumor bed containing residual cancer, the number of residually positive lymph nodes, and the longest diameter of the largest residual nodal metastasis [16]. Raw scores are then categorized into RCB classes using pre-defined cut points, with a score of 0 representing pCR and scores 1–3 representing progressively greater extents of residual cancer. In addition, RCB has been shown to provide prognostic value independent of yAJCC stage for patients with post-treatment stage II and III disease [16].

The post-neoadjuvant yAJCC staging system has also been demonstrated to have prognostic value [15]. yAJCC parses patients into five groups and nine subgroups based on the extent and characteristics of residual disease [2]. The system considers three parameters for pathologic staging: tumor in the breast, tumor in local lymph nodes, and metastases. Residual tumor in the breast (ypT) is determined by pathologic size and extension, as well as chest wall or skin invasion and pre-treatment inflammatory carcinoma. Residual nodal involvement (ypN) is determined primarily by the number of positive lymph nodes, although characteristics of these nodes (e.g., matted or

fixed) also affect this score. Finally, yM designates distant metastases, and is typically established clinically before treatment. A combined ypTNM designation yields an overall yAJCC stage, ranging from 0 to IV, with subgroups within stages I–III.

In this study, we compare pCR, RCB, and yAJCC to determine how well these staging systems predicted post-treatment recurrence using the I-SPY 1 trial dataset [3, 4]. Our goal was to determine strengths of these systems as well as areas in which they could be improved, to help guide future refinements of post-neoadjuvant staging.

## Materials and methods

Our group has previously published a detailed description of the methods employed in the I-SPY 1 TRIAL (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis) [3, 4]. Briefly, I-SPY 1 was a limited-access cooperative group trial for women with locally advanced (stage II and III) breast cancer treated with neoadjuvant, anthracycline-based chemotherapy. The institutional review boards of all participating sites approved the I-SPY 1 TRIAL protocol (CALGB150007/150012; ACRIN 6657). Our primary outcome was recurrence-free survival (RFS) according to the STEEP criteria.

In the current analysis, we included participants who had completed neoadjuvant chemotherapy, undergone definitive surgery, and who had both RCB and yAJCC stages determined from their post-treatment surgical resection specimens. We excluded patients treated with neoadjuvant or adjuvant trastuzumab because at time of study initiation, trastuzumab was given at physician discretion, typically to patients who were felt not to be responding to then-standard of care regimens. This lowered the proportion of HER2-positive samples in our study population, but there were no other significant differences in pre-treatment patient characteristics or RFS of our study population compared to the full I-SPY 1 TRIAL cohort. To evaluate the impact of exclusion of patients who received

trastuzumab, we conducted a separate analysis including these patients; results were not found to differ significantly from those presented here.

Pathologists at participating sites evaluated pCR, RCB, and yAJCC stage components at the time of surgery. PCR was defined as the absence of invasive carcinoma in both breast and lymph node tissue. RCB score and class were determined using the MD Anderson Cancer Center's online calculator (<http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3>). To standardize measurements across several sites and minimize inter-observer variability, all study pathologists were trained on RCB calculation during an instruction session at MD Anderson Cancer Center or via an online webinar. The first five specimens from each pathologist were centrally re-reviewed.

yAJCC stage was determined using the 7th edition of the AJCC staging guidelines. Subgroups (IIA/B, IIIA/B/C) were also calculated, but were not used in the recurrence analysis because of insufficient subgroup sample sizes. When nests of tumor cells in fibrotic stroma were observed after treatment, the distance over which the tumor nests spread was used for the measurement of tumor size (ypT).

Recurrence-free survival (RFS) was the primary outcome of interest, and was calculated in accordance with STEEP criteria [8]. We constructed Kaplan–Meier survival curves to stratify patients by yAJCC stage and RCB class overall and within HR/HER2 subtypes, and we applied the log-rank test to evaluate for significant curve separation. Patients were removed from at-risk groups when they were censored or experienced recurrence or death. We used a Cox proportional hazards model to assess clinical and pathological parameters as predictors of RFS, and we computed Harrell's C statistics, a concordance measure used to assess a model's predictive performance, to compare systems. We also adopted recursive partitioning to identify variables that best predict RFS. Recursive partitioning is a multivariable analysis tool that builds a decision tree that most effectively predicts the outcome of interest (RFS) by splitting the total group into subgroups based on input variables. The statistical programming environment R was used to carry out the recursive partitioning, using the *rpart* package. Cox proportional hazards analyses were carried out in STATA version 11.

## Results

### Study participants

Among the 237 women enrolled in the I-SPY 1 TRIAL, 201 completed neoadjuvant chemotherapy and post-treatment surgery, and had both RCB and yAJCC data available for

analysis. Median age was 48 years (range 26–68). Excluding patients treated with trastuzumab, we analyzed 162 patients (Fig. 1). Table 2 summarizes the patients' pre-treatment characteristics. Most (51%) had clinical stage II cancers. Most had hormone-receptor (ER or PR) positive tumors (64%), and 18% had HER2 positive tumors. Median follow-up time for patients was 6.7 years. After completing chemotherapy, 37 patients (23%) had achieved pCR.

### RCB and yAJCC identify patients at high risk of early relapse

Figure 2 shows recurrence-free survival (RFS) stratified by RCB class, and Fig. 3 shows recurrence-free survival (RFS) based on yAJCC stage. Patients with pCR (i.e., RCB 0 and yAJCC 0) had overall low recurrence rates (92% 5-year RFS), and were at a significantly lower risk of recurrence when compared to patients with any amount of residual disease (Table 3). In comparison, patients with low to intermediate residual disease (RCB 1 or 2, yAJCC 1 or 2) had a ~4-fold increased risk of relapse/death; the increased risk was ~11-fold for patients with extensive residual disease (RCB3, yAJCC3). When we compared patients with RCB 3 to patients with RCB <3, patients with RCB 3 remained significantly more likely to recur (RCB 3 vs. RCB 0/1/2: Hazard Ratio 3.37 (1.96–5.80)  $p < 0.0001$ ). Similarly, patients with yAJCC III had significantly worse




Fig. 1 Consort diagram: patients available for analysis

**Table 2** Patient characteristics

Pre-surgery characteristics	<i>n</i> (%)
Total patients analyzed	162
Median age (years) (range)	48 (26–68)
Pre-menopausal	77 (48)
Race	
Caucasian	123 (76)
African American	28 (17)
Asian	6 (4)
Other/not specified	5 (3)
Clinical tumor size (cm) (range)	7 (0–18)
Histologic grade	
Grade I	14 (9)
Grade II	72 (44)
Grade III	73 (45)
Indeterminate	3 (2)
Clinical stage	
I	3 (2)
IIA	37 (23)
IIB	46 (28)
IIIA	53 (33)
IIIB	11 (7)
IIIC	4 (2)
Hormone and HER2 receptors	
HER2+	29 (18)
HR+/HER2–	87 (54)
HR–/HER2–	46 (28)
Neoadjuvant treatment	
AC only	11 (7)
AC + T	150 (92)
AC + T + Other	1 (1)
AC + T + Other	1 (1)
Post-surgery patient characteristics	
Histologic grade	
Grade I	20 (12)
Grade II	64 (40)
Grade III	32 (20)
No invasive disease present or not reported	46 (28)
pCR (also RCB class 0, yAJCC stage 0)	37 (23)
RCB class	
1	13 (8)
2	75 (46)
3	37 (23)
yAJCC stage	
I	33 (20)
II	52 (32)
IIA	31 (19)
IIB	21 (13)
III	40 (25)
IIIA	25 (15)

**Table 2** continued

Pre-surgery characteristics	<i>n</i> (%)
<i>IIIB</i>	2 (1)
<i>IIIC</i>	13 (8)
Adjuvant systemic therapy	
Any hormonal therapy	135 (83)
Aromatase Inhibitor	73 (45)
Tamoxifen	62 (38)
Ovarian suppression	14 (9)
Ovarian ablation	6 (4)

*HR* hormone receptor, *ER* estrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2, *AC* doxorubicin/cyclophosphamide, *T* paclitaxel, *pCR* pathologic complete response, *yAJCC* American Joint Committee on Cancer post-neoadjuvant staging, *RCB* residual cancer burden


RFS than patients with yAJCC < III (yAJCC III vs yAJCC 0/I/II: Hazard Ratio 3.40 (1.99–5.83),  $p < 0.0001$ ). Both RCB 3 and yAJCC III remained significant predictors of high recurrence risk after adjusting for age, clinical stage, and HR status, both when RCB and yAJCC were stratified into four classes and when they were dichotomized (RCB 0/1/2 vs 3 and yAJCC 0/I/II vs III).

### TN and HER2+ subtyping improves RCB and yAJCC predictive ability

Both RCB and yAJCC show the strongest association with RFS in patients with “triple-negative” (HR–/HER2–, abbreviated TN) cancers (Figs. 2b, 3b). Conversely, patients who had HR+/HER2– tumors had relatively low recurrence rates regardless of RCB or yAJCC class, and neither RCB nor yAJCC significantly associate with RFS within this subtype (Figs. 2c, 3c). Likewise, a comparison of the predictive performances of Cox proportional hazard models constructed for all patients versus within individual subtypes suggests that the staging systems tended to predict RFS more effectively when subtype was taken into account. This is indicated by higher Harrell’s C statistics (an indicator of a model’s predictive ability) for each system within the TN and the HER2+ subtypes versus overall, although this effect was not seen in patients with HR+/HER2– tumors (Table 4). When we analyzed RCB score as a continuous rather than a discrete variable, the continuous score was significantly associated with RFS in all subtypes (Table 5).

### Recursive partitioning selects yAJCC III and RCB 3 as more effective predictors of early relapse than subtype

Recursive partitioning was used to identify the optimal way to separate patients based on their recurrence-free survival.




**Fig. 2 a–d** Recurrence-free survival (RFS) based on residual cancer burden (RCB) for all patients (a) and by subtype (b–d)

We included pCR, RCB, yAJCC, age, and hormone-receptor/HER2 status as potential variables for the model to use. The model initially separated patients by yAJCC, identifying “high-risk” (yAJCC III) and “low-risk” (yAJCC 0/I/II) groups. It subsequently separated patients in the high-risk group by receptor status, and the low-risk group by whether a pCR was achieved (Fig. 4a). In this model, patients who were yAJCC III and TN or HER2+ were at significantly higher risk of relapse than all other patients (Hazard Ratio 8.39 (4.41–15.94),  $p < 0.0001$ ). When yAJCC was excluded as an input variable, recursive partitioning selected RCB as the optimal variable to identify patients who would recur, again separating patients

into “high-risk” (RCB 3) and “low-risk” (RCB 0/1/2) groups. Like yAJCC, the model subdivided the “high-risk” group based on receptor subtype and “low-risk” patients by whether a pCR was achieved (Fig. 4b). In this model, patients with RCB 3 who were TN or HER2+ were at significantly higher risk of early relapse than all other patients (Hazard Ratio: 7.47 (3.83–14.57),  $p < 0.0001$ ).

**yAJCC and RCB stages are often discrepant**

In 34% ( $n = 55$ ) of patients, RCB and yAJCC staging systems were discrepant (Table 6). RCB class was greater than yAJCC in 36 patients, while yAJCC staging was



**Fig. 3 a–d** Recurrence-free survival (RFS) based on American Joint Committee on Cancer (yAJCC) stage for all patients (a) and by subtype (b–d)

greater than RCB in 19 patients. Discrepancies were largely due to unequal weighting of positive lymph nodes in the two systems and the weighting of tumor cellularity in RCB, which is not incorporated into yAJCC. For 11 patients with discrepant RCB and yAJCC scores, pathology slides were available to re-review to qualitatively assess the reasons for the discrepancy. Visual examples of features that commonly led to discrepancy are given in Supplemental Fig. 1. These images show a cancer with low cellularity but many positive nodes that received a higher yAJCC stage than RCB stage (Supplemental Fig. 1a–b), and also illustrate a tumor with high cellularity and no

positive nodes that received an RCB stage greater than yAJCC stage (Supplemental Fig. 1c).

**Discussion**

Pathologic response to treatment after neoadjuvant chemotherapy provides valuable prognostic information. The goal of this analysis was to compare three commonly used staging systems and highlight areas in which these systems differ and could be improved. Our analysis revealed three key findings: (1) RCB and yAJCC identify

**Table 3** Significance of key variables in Cox modeling of RFS

	Univariate		Multivariate <sup>a</sup>	
	Hazard Ratio (CI)	<i>p</i> value	Hazard Ratio (CI)	<i>p</i> value
<b>pCR</b>				
No pCR relative to pCR	5.97 (1.86–19.12)	0.003	9.18 (2.75–30.62)	<0.0001
<b>RCB</b>				
Four classes (relative to RCB 0)				
RCB 1	4.49 (1.07–18.79)	0.04	6.66 (1.57–28.24)	0.01
RCB 2	4.31 (1.29–14.36)	0.02	7.95 (2.29–27.61)	<0.0001
RCB 3	11.07 (3.32–36.91)	<0.0001	24.08 (6.50–89.27)	<0.0001
Dichotomized (RCB 3 relative to RCB 0/1/2)	3.37 (1.96–5.80)	<0.0001	4.02 (2.18–7.54)	<0.0001
<b>yAJCC</b>				
Four classes (relative to yAJCC 0)				
yAJCC I	4.13 (1.14–15.01)	0.03	5.84 (1.59–21.44)	0.01
yAJCC II	4.34 (1.27–14.82)	0.02	11.83 (3.19–43.88)	<0.0001
yAJCC III	10.94 (3.29–36.37)	<0.0001	22.57 (6.02–84.60)	<0.0001
Dichotomized (yAJCC III relative to yAJCC 0/I/II)	3.40 (1.99–5.83)	<0.0001	3.27 (1.73–6.17)	<0.0001

*pCR* pathologic complete response, *yAJCC* American Joint Committee on Cancer post-neoadjuvant staging, *RCB* residual cancer burden, *RFS* recurrence-free survival, *CI* confidence interval, *HR* hormone receptor

<sup>a</sup> Adjusted for clinical stage (III/inflammatory vs. I/II), age, and HR status

patients at high risk of early relapse, (2) predictive ability of these staging systems increases when HR/HER2 subtype is taken into account, and (3) RCB and yAJCC often produce discrepant results, largely driven by differential treatment of lymph nodes and the inclusion of cellularity in calculation of RCB. These findings complement a recent, multi-cohort analysis of RCB [17].

In contrast to pCR, our recursive partitioning analysis suggests that a primary utility of RCB and yAJCC may be to identify patients with residual tumor who are at highest risk of relapse. Specifically, the model identified yAJCC III and (when yAJCC was excluded) RCB 3 as the primary predictors of relapse.

By combining receptor subtype and staging system, recursive partitioning was able to identify a subset of patients that was at exceptionally high risk of early relapse: patients with extensive residual tumor (yAJCC III and/or RCB 3) whose tumors were also TN or HER2+ (three-year RFS for patients with yAJCC III and RCB 3 was 27% and 29%, respectively, within these subtypes). Previous analysis has shown that pCR was more effective at predicting RFS within receptor subtypes than in all cases combined within the I-SPY 1 dataset [4]. Our study extends this finding to patients with varying degrees of residual tumor, in which both RCB and yAJCC staging systems tend to be more predictive of RFS when analyzed by subtype.

The exception to this trend was the HR+/HER2– subtype. The majority of HR+/HER2– patients were at either

intermediate or high risk for recurrence according to RCB (82% of these patients were RCB 2 or 3) and yAJCC (71% of these patients were yAJCC II or III), yet patients with this subtype had better RFS than patients with HER2+ or TN cancers. This result supports previous analysis suggesting that HR+/HER2– tumors may be intrinsically less responsive to chemotherapy [3], and therefore patients with these tumors may be predisposed to lower rates of pCR [7] and more extensive residual tumor. However, it is well known that patients with HR+/HER2– subtype tumors tend to experience lower rates of recurrence than patients with HER2+ or TN tumors, consistent with our results. Notably, using a combined analysis of several cohorts, Symmans and colleagues demonstrated that RCB did predict RFS among HR+/HER2– patients, including between participants at intermediate (RCB 2) and high (RCB 3) predicted risk of relapse [17]. Nonetheless, like in our study, Symmans found that a substantial majority (60%) of patients with HR+/HER2– disease were classified as RCB 2, suggesting potential need for further methods to stratify patients within HR+/HER2– patients.

In contrast to yAJCC, RCB is calculated as a continuous score. Although RCB class was specified using cut points that were determined using a unified cohort in which all subtypes were represented [16], the continuous score may allow for definition of subtype-specific cut points. Although our dataset was not large enough to establish subtype-specific cut points, we nevertheless found that

**Table 4** Comparison of pCR, yAJCC, and RCB as predictors of RFS by subtype

Staging method	Hazard Ratio (95% CI) (relative to pCR/RCB 0/yAJCC 0)	Harrell's C
Overall		
yAJCC		0.683
I	4.13 (1.14–15.01)	
II	4.34 (1.27–14.82)	
III	10.94 (3.29–36.37)	
RCB		0.677
1	4.49 (1.07–18.79)	
2	4.31 (1.29–14.36)	
3	11.07 (3.32–36.91)	
no pCR	5.97 (1.86–19.12)	0.597
HR+/HER2– ( $n = 87$ $d = 26$ ) <sup>a</sup>		
yAJCC		0.640
I	>25 (n/a <sup>b</sup> )	
II	>25 (n/a <sup>b</sup> )	
III	>25 (n/a <sup>b</sup> )	
RCB		0.641
1	>25 (n/a <sup>b</sup> )	
2	>25 (n/a <sup>b</sup> )	
3	>25 (n/a <sup>b</sup> )	
no pCR	>25 (n/a <sup>b</sup> )	0.552
HER2+ ( $n = 29$ $d = 11$ ) <sup>a</sup>		
yAJCC		0.713
I	18.06 (1.98–164.77)	
II	3.39 (0.31–37.40)	
III	20.87 (2.29–190.48)	
RCB		0.725
1	11.75 (1.21–114.30)	
2	6.54 (0.73–58.55)	
3	22.01 (2.09–232.25)	
no pCR	9.65 (1.23–75.7)	0.705
TN ( $n = 46$ $d = 17$ ) <sup>a</sup>		
yAJCC		0.802
I	1.73 (0.24–12.27)	
II	4.81 (0.88–26.32)	
III	21.24 (4.49–100.55)	
RCB		0.774
1	<0.0001 (n/a <sup>c</sup> )	
2	3.65 (0.74–18.10)	
3	16.92 (3.59–79.66)	
no pCR	6.04 (1.38–26.49)	0.669
HER2+ or TN ( $n = 75$ $d = 24$ ) <sup>a</sup>		
yAJCC		0.764
I	4.45 (1.11–17.80)	
II	4.08 (1.02–16.31)	
III	20.56 (5.78–73.18)	
RCB		0.746

**Table 4** continued

Staging method	Hazard Ratio (95% CI) (relative to pCR/RCB 0/yAJCC 0)	Harrell's C
1	5.18 (1.05–25.69)	
2	4.54 (1.25–16.51)	
3	18.02 (4.98–65.21)	
no pCR	7.1 (2.14–23.55)	0.678

pCR pathologic complete response, yAJCC American Joint Committee on Cancer post-neoadjuvant staging, RCB residual cancer burden, RFS recurrence-free survival, CI confidence interval, HR hormone receptor, HER2 human epidermal growth factor receptor 2, TN triple-negative

<sup>a</sup>  $n$  = total number of patients in category,  $d$  = number of patients who experienced recurrence and/or death in category

<sup>b</sup> CI could not be calculated because no relapses/deaths occurred in the pCR group

<sup>c</sup> CI could not be calculated because no relapses/deaths occurred in the RCB1 group

**Table 5** Significance of the association between RFS and the continuous RCB index and RCB class within subtypes

	$p$ value
TN ( $n = 29$ )	
RCB class <sup>a</sup>	<0.0001
Continuous RCB index <sup>b</sup>	<0.0001
HR + HER2– ( $n = 79$ )	
RCB class <sup>a</sup>	0.109
Continuous RCB index <sup>b</sup>	0.0053
HER2 + ( $n = 17$ )	
RCB class <sup>a</sup>	0.0137
Continuous RCB index <sup>b</sup>	0.0091


<sup>a</sup> Evaluated with log-rank  $p$  tests of a Kaplan–Meier curve

<sup>b</sup> Evaluated with Wald test  $p$  value from a univariate Cox model

within each subtype, continuous RCB score was significantly associated with RFS (notably, categorical RCB score was not significantly associated with RFS in HR+/HER2– patients). In the future, the ability to define subtype-specific RCB class cut points may make RCB particularly valuable as a post-neoadjuvant risk-stratification system.

In our dataset, different weighting of lymph nodes and tumor cellularity were the primary drivers of discrepancies between RCB and yAJCC. In discrepant cases, if one staging system identified the patient as high risk, then that patient tended to have increased rate of early recurrence regardless of how the other system ranked her tumor. This suggests that there may be benefit to computing both scores for patients to identify those at highest risk of relapse. Sample-size limitations prevented us from defining subsets





**Fig. 4 a and b** Recursive partitioning models of predictors of RFS. Under each branch, the calculated risk is listed. Beneath that, the number of patients with a recurrence or death is divided by the

number of patients within each category. Figure 4b was generated when yAJCC was excluded from the model

**Table 6** Concordance and discordance of RCB and yAJCC risk classifications

RCB class <i>n(d)</i>	yAJCC stage <i>n(d)</i>				Total
	0	I	II	III	
0	37 (3)	0	0	0	37 (3)
1	0	9 (3)	4 (2)	0	13 (5)
2	0	24 (7)	36 (10)	15 (6)	75 (23)
3	0	0	12 (5)	25 (18)	37 (23)
Total ( <i>n</i> = 162)	37 (3)	33 (10)	52 (17)	40 (24)	162 (54)

*n* = total number of patients in category, (*d*) = number of patients who experienced recurrence and/or death in category

RCB residual cancer burden, yAJCC American Joint Committee on Cancer post-neoadjuvant staging

of patients based on nodes or cellularity in which one system out-performed the other. However, as post-neoadjuvant pathological staging continues to evolve, our results suggest that an avenue to improve these systems may be to re-evaluate the role of cellularity and number of positive lymph nodes, drawing from apparent strengths of RCB and yAJCC, respectively.

Although pathologic staging using one or more of the systems reviewed here is routinely carried out following neoadjuvant chemotherapy, there are known limitations to calculation of each of these scores. For RCB, cellularity and overall dimensions of the tumor bed are subjective, and the tumor bed can show heterogeneity in response, complicating calculation of cellularity and dimensions. In the I-SPY trial, standardized training for pathologists, complemented by diagrams and a standard protocol for slide review, were used to ensure consistent calculation of cellularity and tumor bed size. For yAJCC, the presence of scattered foci of residual tumor in the tumor bed may compromise calculation of residual tumor size. Finally, inclusion or exclusion of ductal carcinoma in situ may vary in determination of pCR. In our study, the presence of residual DCIS in the absence of other residual tumor was considered to be pCR, reflecting a typical, but not universal, definition of pCR. Although residual ductal carcinoma in situ was found to predict adverse outcomes in one recent cohort [18], it has not found to adversely affect outcomes in other studies [9, 11]; its impact on outcomes remains a topic of investigation.

The limitations of our analysis include short median follow-up time (6.7 years) and small sample size. The short follow-up has the greatest impact on the HR+/HER2–subset, in which low overall rates of early relapse limited additional stratification by yAJCC and RCB. In addition, trastuzumab became standard of care for HER2+ patients while this study was ongoing; prior to then, it was administered at physician discretion. By excluding patients who received trastuzumab, we avoided introducing this source of bias into our analysis, but future analyses of post-neoadjuvant staging should assess this staging in cohorts in which the most up to date chemotherapy guidelines are reflected. To assess the effect of excluding patients who received trastuzumab, we conducted an analysis on the complete cohort, including these patients (data not shown), and found no significant differences from the results we present here. Finally, inter-observer variability in pathologic assessment was not addressed in this study, although it has previously been shown to be high among a small sample of pathologists evaluating RCB [12].

In summary, we have shown that RCB and yAJCC staging systems identify patients who are at highest risk for early recurrence, in contrast to pCR, which selects patients at lowest risk for relapse. In addition, our analysis suggests that combining pathologic staging with HR/HER2 subtyping further stratifies patients' risk, and that triple-negative status combined with high disease burden poses the greatest risk to RFS. Continuous RCB score was found to be significantly associated with RFS within each subtype, suggesting that distinct risk classification cut points could be determined for each subtype to improve RFS predictions. Finally, we found that RCB and yAJCC frequently produce discrepant risk predictions, resulting primarily from different treatments of lymph nodes and tumor cellularity. Patients with high tumor cellularity may particularly benefit from calculation of RCB in addition to routine yAJCC staging. Altogether, our findings indicate that tumor cellularity, lymph node status and receptor status are useful areas of further investigation for evolving post-neoadjuvant tumor staging systems.

**Acknowledgements** The authors would like to thank the patients in the I-SPY 1 TRIAL, as well as the study staff who support it. We would also like to thank the I-SPY Data & Publications Committee and the CALGB Review committee for their reviews and comments on this manuscript.

**Funding sources** National Cancer Institute Specialized Program of Research Excellence in Breast Cancer (CA58207), American College of Radiology Imaging Network (CA079778 and CA080098), Cancer and Leukemia Group B (CA31964 and CA33601), National Cancer Institute Center for Bioinformatics, The Breast Cancer Research Foundation, Bruce and Martha Atwater, and “Give Breast Cancer the Boot.” Additional funding came from grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, M.D., Chair) and to the Alliance

Statistics and Data Center (Daniel J. Sargent, Ph.D., CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. The following institutions participated in this study: (1) Georgetown University Medical Center, Washington, DC, Bruce Cheson, M.D., supported by CA77597. (2) Memorial Sloan-Kettering Cancer Center, New York, NY, Clifford A. Hudis, M.D., supported by CA77651. (3) University of Alabama, Birmingham, AL (ECOG). (4) University of California at San Francisco, San Francisco, CA, Charles J. Ryan, M.D., supported by CA60138. (5) University of Chicago, Chicago, IL, Hedy L. Kindler, M.D., supported by CA41287. (6) University of Minnesota, Minneapolis, MN, Bruce A. Peterson, M.D., supported by CA16450. (7) University of North Carolina at Chapel Hill, Chapel Hill, NC, Thomas C. Shea, M.D., supported by CA47559. (8) University of Pennsylvania, Philadelphia, PA (ECOG). (9) University of Texas Southwestern Medical Center, Dallas, TX, supported by CA37347. (10) University of Washington, Seattle WA (SWOG).

## References

- Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol* 23:3676–3685. doi:10.1200/JCO.2005.07.032
- Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 17:1471–1474
- Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, Investigators IST (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). *Breast Cancer Res Treat* 132:1049–1062. doi:10.1007/s10549-011-1895-2
- Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N (2012) Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657. *J Clin Oncol* 30:3242–3249. doi:10.1200/JCO.2011.39.2779
- Esserman LJ, Woodcock J (2011) Accelerating identification and regulatory approval of investigational cancer drugs. *JAMA* 306:2608–2609. doi:10.1001/jama.2011.1837
- Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. *Cancer* 95:681–695
- Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast

- cancer subtype and pathologic complete response to neoadjuvant chemotherapy. *Eur J Cancer* 48:3342–3354. doi:[10.1016/j.ejca.2012.05.023](https://doi.org/10.1016/j.ejca.2012.05.023)
8. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. *J Clin Oncol* 25:2127–2132. doi:[10.1200/JCO.2006.10.3523](https://doi.org/10.1200/JCO.2006.10.3523)
  9. Jones RL, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE (2006) Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. *Br J Cancer* 94:358–362. doi:[10.1038/sj.bjc.6602950](https://doi.org/10.1038/sj.bjc.6602950)
  10. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Puztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol* 26:1275–1281. doi:[10.1200/JCO.2007.14.4147](https://doi.org/10.1200/JCO.2007.14.4147)
  11. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Puztai L (2007) Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. *J Clin Oncol* 25:2650–2655
  12. Peintinger F, Hatzis C, Morkowski J, Hubbard R, Albarracin CT, Qureshi G, Puztai L, Symmans WF (2008) Inter-pathologist agreement of residual cancer burden (rcb) assessment in breast cancer after treatment with preoperative chemotherapy. *J Clin Oncol* 26:576 (**Meeting Abstracts**)
  13. Prowell TM, Pazdur R (2012) Pathological complete response and accelerated drug approval in early breast cancer. *N Engl J Med* 366:2438–2441. doi:[10.1056/NEJMp1205737](https://doi.org/10.1056/NEJMp1205737)
  14. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. *Br J Cancer* 91:2012–2017. doi:[10.1038/sj.bjc.6602235](https://doi.org/10.1038/sj.bjc.6602235)
  15. Sinn HP, Helmchen B, Wittekind CH (2010) TNM classification of breast cancer: changes and comments on the 7th edition. *Der Pathologe* 31:361–366
  16. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniacka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Puztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. *J Clin Oncol* 25:4414–4422
  17. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Puztai L, Hatzis C, Hortobagyi GN (2017) Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. *J Clin Oncol* 35:1049–1060. doi:[10.1200/JCO.2015.63.1010](https://doi.org/10.1200/JCO.2015.63.1010)
  18. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 30:1796–1804. doi:[10.1200/JCO.2011.38.8595](https://doi.org/10.1200/JCO.2011.38.8595)